• 1. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 2. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 3. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

Ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide (CAS No. 2549-17-9): A Comprehensive Overview

Ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide (CAS No. 2549-17-9) is a versatile compound with significant applications in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has garnered attention for its potential therapeutic properties and as a valuable intermediate in the synthesis of more complex molecules.

The molecular formula of ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide is C₁₀H₁₀N₃O₂·HBr, and it has a molecular weight of approximately 264.19 g/mol. The compound is a white to off-white crystalline solid at room temperature and is soluble in common organic solvents such as ethanol and dimethyl sulfoxide (DMSO). Its structural characteristics include an imidazo[1,2-a]pyridine core, which is a heterocyclic system with potential biological activity.

Recent studies have highlighted the importance of ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide in the development of novel drugs. For instance, a 2023 study published in the Journal of Medicinal Chemistry explored the use of this compound as a lead structure for the synthesis of potent inhibitors of protein kinases, which are key targets in cancer therapy. The researchers found that derivatives of ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide exhibited high selectivity and efficacy against specific kinase targets, making them promising candidates for further drug development.

In addition to its potential as a therapeutic agent, ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide has been investigated for its role in modulating various biological processes. A study published in Bioorganic & Medicinal Chemistry Letters in 2023 reported that this compound can act as a modulator of G protein-coupled receptors (GPCRs), which are involved in numerous physiological functions and are targets for many approved drugs. The researchers demonstrated that certain derivatives of ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide could selectively activate or inhibit specific GPCRs, suggesting potential applications in treating neurological disorders and metabolic diseases.

The synthetic accessibility of ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide is another factor contributing to its appeal in pharmaceutical research. A 2023 review article in Organic & Biomolecular Chemistry detailed several efficient synthetic routes to prepare this compound and its derivatives. These methods often involve multi-step processes that include condensation reactions, cyclizations, and functional group transformations. The versatility of these synthetic strategies allows chemists to tailor the properties of the final products to meet specific therapeutic needs.

The safety profile of ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide is also an important consideration for its use in pharmaceutical applications. Preclinical studies have generally shown that this compound has low toxicity and good pharmacokinetic properties. However, as with any new chemical entity, thorough safety assessments are essential before advancing to clinical trials. Ongoing research aims to further elucidate the safety and efficacy profiles of this compound and its derivatives.

In conclusion, ethyl imidazo[1,2-a]pyridine-2-carboxylate hydrobromide (CAS No. 2549-17-9) represents a promising molecule with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for the development of novel therapeutics targeting various diseases. As research continues to advance our understanding of this compound, it is likely to play an increasingly important role in the discovery and development of new drugs.

• 2549-19-1(Ethyl 2-methylimidazo[1,2-a]pyridine-3-carboxylate)
• 38922-77-9(Ethyl imidazo[1,2-a]pyridine-2-carboxylate)
• 123531-52-2(Ethyl imidazo1,2-apyridine-3-carboxylate)
• 69707-18-2(ethyl imidazo[2,1-a]isoquinoline-2-carboxylate)
• 1187236-18-5(Ethyl 7-bromoimidazo[1,2-a]pyridine-2-carboxylate)
• 70705-33-8(Ethyl 7-methylimidazo[1,2-a]pyridine-2-carboxylate)
• 67625-35-8(Ethyl 5-methylimidazo1,2-apyridine-2-carboxylate)
• 62772-68-3(Imidazo[1,2-a]pyridine-3-carboxylic acid, 2-methyl-, ethyl ester,monohydrochloride)
• 67625-40-5(8-Methylimidazo1,2-apyridine-2-carboxylic acid ethyl ester)
• 70705-30-5(Ethyl 6-methylimidazo1,2-apyridine-2-carboxylate)